Market Data graphic

Life Sciences

You are here

The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.

Life sciences companies listed on CSE

Hempsana Holdings Ltd. is a cannabis derivatives extraction and purification and cannabis infused end-product manufacturing company. It offers cannabinoid derivatives for medical and retail sales channels, end-product formulations, and service offerings for Extraction and Post-Processing.  

Herbal Dispatch owns and operates leading cannabis e-commerce platforms and is dedicated to providing top quality cannabis to informed consumers at affordable pricing.

Herbal Dispatch's flagship cannabis marketplace, Herbal Dispatch, is a trusted source for exclusive access to small-batch craft cannabis flower and a wide-array of other product formats.

Herbal Dispatch’s common shares trade on the Canadian Securities Exchange under the symbol “HERB”.

 

HYTN Innovations Inc. formulates, manufactures, markets, and sells premium products that contain psychoactive and psychotropic compounds. The company’s mission is to become the top provider of these products in all federally regulated markets. To achieve this, the company focuses on identifying market opportunities in order to quickly bring its innovative products to market through its elevated development platform.

IMCC is an international medical cannabis company, and a well-known Israeli brand of medical cannabis products. In Europe, IMCC is establishing a fully operational, vertically integrated medical cannabis business spearheaded by its distribution arm in Germany and augmented by strategic agreements with certified EU-GMP Standard suppliers, making it one of the only medical cannabis companies with fully integrated operations in Europe. IMCC intends to leverage IMCC's brand to establish a foothold in emerging medical cannabis markets including Germany, Portugal and Greece.

The Corporation's business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products; (ii) research and development of non-pharmaceutical products for third parties in exchange for fees and/or royalties; and (iii) research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales.

Irwin Naturals is a nutraceutical company that distributes dietary supplements to more than 100,000 retailers, including mass-market retailers.

Investor Note: In addition to the 3,369,368 Subordinate Voting Shares that are listed and trading, there are (i) 340,300 subordinate voting shares reserved for issuance pursuant to the conversion rights attached to the Proportionate Voting Shares of Irwin Naturals Inc. (ii) 18,240 subordinate voting shares reserved for issuance pursuant to the conversion rights attached to the Multiple Voting Shares of Irwin Naturals Inc.; (iii) 303,999,878 subordinate voting shares reserved for issuance pursuant to the exchange rights attached to the Class B Non-Voting Shares of Irwin Naturals, an indirect, wholly-owned subsidiary of Irwin Naturals Inc.; and (iv) 20,000 subordinate voting share purchase warrants.  The total number of equity shares assuming all are converted or exchanged, as applicable, into the listed class would be 307,747,786.

The Company is engaged in the commercialization of proprietary diagnostic products for breast cancer. Its business strategy is to complete the commercial development of 360 degree, true 3D breast imaging technology for early diagnosis of breast cancer. The Company holds a license under a license agreement to make, have made, use, offer for sale, import, and sell products and services and to practice processes and methods in the field of human diagnostics and therapeutics in the United States and any other countries where approvals are granted or where patent rights may exist in the future with respect to certain licensed patent rights.

Jolt Health Inc., is a specialized health and wellness company offering pharmaceutical and therapeutic products with proven technologies for which it has the exclusive rights to produce, package and sell thoughout  Europe, North America and the United Kingdom. Many of the products are market-ready, with proven history of significant sales. The Company is focused on the global sexual wellness and enhancement market. 

Jushi Holdings Inc. is a vertically-integrated, multi state cannabis operator led by an industry leading management team. In the United States Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts and competitive applications. Jushi strives to maximize shareholder value while delivering high quality products across all levels of the cannabis ecosystem.

Contact The Team

How can we help you?

Contact the CSE team to find out more.